Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2018

  • ID: 4482755
  • Drug Pipelines
  • 209 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Cellphire Inc
  • FirstString Research Inc
  • Humanetics Corp
  • Nohla Therapeutics Inc
  • RedHill Biopharma Ltd
  • MORE
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2018, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 7, 2, 44, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Cellphire Inc
  • FirstString Research Inc
  • Humanetics Corp
  • Nohla Therapeutics Inc
  • RedHill Biopharma Ltd
  • MORE
Introduction

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Consegna Pharma Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco AS, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Medesis Pharma SA, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2018 (Contd..2), H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2018 (Contd..3), H1 2018

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aeolus Pharmaceuticals Inc
  • Angion Biomedica Corp
  • Atox Bio Ltd
  • BCN Biosciences LLC
  • Bolder Biotechnology Inc
  • Cellerant Therapeutics Inc
  • Cellphire Inc
  • Chrysalis BioTherapeutics Inc
  • Cleveland BioLabs Inc
  • Consegna Pharma Inc
  • Daiichi Sankyo Co Ltd
  • FirstString Research Inc
  • Galera Therapeutics Inc
  • Genzyme Corp
  • GNI Group Ltd
  • Humanetics Corp
  • Meabco AS
  • Medesis Pharma SA
  • Neumedicines Inc
  • Nohla Therapeutics Inc
  • Onconova Therapeutics Inc
  • Original BioMedicals Co Ltd
  • PharmaIN Corp
  • Pluristem Therapeutics Inc
  • RDD Pharma Ltd
  • RedHill Biopharma Ltd
  • RxBio Inc
  • SK Chemicals Co Ltd
  • Soligenix Inc
  • Synedgen Inc
  • Tonix Pharmaceuticals Holding Corp
  • TSRL Inc
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll